Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA

被引：0
|
作者：
Barnett, Reagan
Lanka, Sree M.
Clemens, Keelia M.
Kiedrowski, Lesli Ann
Babiker, Hani M.
Bryce, Alan Haruo
Meyer, Haley M.
Choi, Yujin
Garje, Rohan
Gao, Xin
Chang, Richard Y.
Jang, Albert
Gulhati, Pat
Bilen, Mehmet Asim
Barata, Pedro C.
机构：
[1] Guardant Hlth Inc, Redwood City, CA USA
[2] Tulane Univ, New Orleans, LA USA
[3] Mayo Clin Florida, Jacksonville, FL USA
[4] Mayo Clin, Phoenix, AZ USA
[5] Mayo Clin, Scottsdale, AZ USA
[6] Emory Univ, Atlanta, GA USA
[7] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[8] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[9] Harvard Med Sch, Boston, MA USA
[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[11] Tulane Univ, Sch Med, New Orleans, LA USA
[12] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[13] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2561
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma
    Graf, Ryon P.
    Fisher, Virginia
    Huang, Richard S. P.
    Hamdani, Omar
    Gjoerup, Ole V.
    Stanke, Jennifer
    Creeden, James
    Levy, Mia A.
    Oxnard, Geoffrey R.
    Gupta, Shilpa
    JCO PRECISION ONCOLOGY, 2022, 6
  • [22] Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment
    Tina Krieger
    Isobel Pearson
    Judith Bell
    Jim Doherty
    Paul Robbins
    Diagnostic Pathology, 15
  • [23] The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study
    Hyunho Kim
    Ji Eun Lee
    Sook Hee Hong
    Myung Ah. Lee
    Jin Hyoung Kang
    In-Ho Kim
    BMC Cancer, 19
  • [24] The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study
    Kim, Hyunho
    Lee, Ji Eun
    Hong, Sook Hee
    Lee, Myung Ah.
    Kang, Jin Hyoung
    Kim, In-Ho
    BMC CANCER, 2019, 19 (01)
  • [25] Improved clinical outcomes in patients received treatment beyond tumor progression with AdAPT-001+/- a checkpoint inhibitor
    Conley, Anthony P.
    Reid, Tony
    Larson, Chris
    Oronsky, Bryan
    Caroen, Scott
    Stirn, Meaghan
    Burbano, Erica
    Abrouk, Nacer
    Roland, Christina L.
    Williams, Jeannie
    Kennedy, Lucy B.
    CANCER RESEARCH, 2024, 84 (07)
  • [26] Short interval circulating tumor DNA (ctDNA) kinetics as a predictor of tumor response in patients with gastrointestinal (GI) cancer receiving immune checkpoint inhibitor (ICI)-based treatment.
    Chakrabarti, Sakti
    Bajor, David L.
    Lumish, Melissa Amy
    Conces, Madison
    Mohamed, Amr
    Mahipal, Amit
    Selfridge, J. Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 836 - 836
  • [27] Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer
    Di Federico, Alessandro
    Alden, Stephanie Leigh
    Smithy, James William
    Ricciuti, Biagio
    Alessi, Joao Victor Machado
    Wang, Xinan
    Lamberti, Giuseppe
    Pecci, Federica
    Gandhi, Malini Marion
    Spurr, Liam Flinn
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Early circulating tumor DNA (ctDNA) changes during treatment with immune checkpoint inhibitors (ICI) as a predictor of clinical outcomes in patients (pts) with advanced stage melanoma/skin cancer.
    Ma, Vincent T.
    Park, Yeonhee
    Patel, Janmesh. D.
    Harris, Madison S.
    Mannino, Matthew C.
    Schehr, Jennifer L.
    Birbrair, Alexander
    Zhao, Shuang
    Lang, Joshua Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 225 - 225
  • [29] Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naive and -experienced patients with metastatic melanoma treated with lifileucel, a tumorinfiltrating lymphocyte (TIL) cell therapy.
    Kluger, Harriet M.
    Sarnaik, Amod
    Chesney, Jason Alan
    Lewis, Karl D.
    Weber, Jeffrey S.
    Gogas, Helen
    In, Gino Kim
    Terheyden, Patrick Andres Maximilian
    Lee, Sylvia
    Jagasia, Madan H.
    Masteller, Emma
    Qi, Rongsu
    Gontcharova, Viktoria
    Shi, Wen
    Fiaz, Rana
    Sulur, Giri
    Wu, Renee Xiao
    Chen, Guang
    Thomas, Sajeve Samuel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected "cold" tumors enrolled in early clinical trials (CT).
    Gadea, Omar Saavedra Santa
    Hernando-Calvo, Alberto
    Berche, Roger
    Vieito, Maria
    Brana, Irene
    Matos, Ignacio
    Alonso, Guzman
    Galvao, Vladimir
    Azaro, Analia
    Oberoi, Honey Kumar
    Wornham, Natassia Ann
    Ros, Javier
    Bejar, Juan Francisco Grau
    Garcia, Carmen
    Macarulla, Teresa
    Capdevila, Jaume
    Elez, Elena
    Tabernero, Josep
    Dienstmann, Rodrigo
    Garralda, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345